Publications by authors named "Samuel Lindner"
The Value of Transradial: Impact on Patient Satisfaction and Health Care Economics.
Interv Cardiol Clin
January 2020
This review summarizes the impact of transradial access for cardiac catheterization and percutaneous coronary intervention related to patient satisfaction, patient safety, and health care costs. In studies comparing transradial versus transfemoral approach, transradial access causes less bleeding and less vascular access site complications and provides a mortality benefit in patients with acute coronary syndromes. Transradial access improves patient satisfaction related to site tolerability by reducing pain and discomfort, and facilitating early ambulation with reduced length of stay.
View Article and Find Full Text PDFContrast-induced acute kidney injury (AKI) is a common and severe complication of percutaneous coronary intervention (PCI). Despite its substantial burden, contemporary data on the incremental costs of AKI are lacking. We designed this large, nationally representative study to examine: (1) the independent, incremental costs associated with AKI after PCI and (2) to identify the departmental components of cost contributing to the incremental costs associated with AKI.
View Article and Find Full Text PDFImaging Review of Common and Rare Causes of Stroke in Children.
Top Magn Reson Imaging
December 2018
Article Synopsis
- Vascular injury is a significant cause of death and illness in kids aged 29 days to 18 years, but it's often overlooked since it's less common than in adults.
- The article discusses various causes of pediatric stroke, including those related to the heart, infections, autoimmune disorders, trauma, and genetics.
- It emphasizes the importance of advanced noninvasive imaging techniques for accurately diagnosing pediatric strokes and differentiating them from similar conditions.
Background: Despite rapid clinical adoption of novel anticoagulants, it is unknown whether outcomes differ among patients with worsening renal function (WRF) taking these new drugs compared with warfarin. We aimed to determine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding) end points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial) differed among participants with WRF taking rivaroxaban and those taking warfarin.
Methods: After excluding patients without at least 1 follow-up creatinine measurement (n=1624), we included all remaining patients (n=12 612) randomly assigned to either rivaroxaban or dose-adjusted warfarin.